Table 3. Association between inflammation-based parameters and clinicopathological factors in patients with breast cancer.

Variables	CRP			LMR			NLR			PLR
	L	H	P	L	H	P	L	H	P	L	H	P
Age (y)
<50	59	2	0.08	8	53	0.69	31	30	0.67	39	22	0.15
≥50	209	26		38	197		128	107		173	62
TS
<20	134	9	0.08	21	122	0.75	86	57	0.04	107	36	0.25
≥20	134	5		25	128		73	80		105	48
ER
(–)	38	5	0.58	5	48	0.65	25	18	0.62	37	6	0.03
(+)	230	23		41	212		134	119		175	78
PgR
(–)	68	6	0.82	9	65	0.46	38	36	0.69	51	23	0.55
(+)	200	22		37	185		121	101		161	61
HER2
(–)	222	25	0.59	38	209	0.83	135	112	0.53	181	66	0.17
(+)	46	3		8	41		24	25		31	18
LN
(–)	191	18	0.51	32	177	0.86	120	89	0.06	158	51	0.02
(+)	77	10		14	73		39	48		54	33
NG
1–2	183	12	1	30	172	0.61	111	91	0.45	143	59	0.68
3	83	9		16	76		46	46		68	24

Abbreviations: CRP, C-reactive protein; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; TS, tumor size; L, low inflammation-based parameter group; H, high inflammation-based parameter group; P, P-value; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; LN, lymph node involvement; NG, nuclear grade.